BR0106601A - Pharmaceutical composition containing bisphosphonate for the treatment of diseases related to calcium and / or phosphate metabolism, their use in the preparation of medicament for the treatment of diseases related to calcium and / or phosphate metabolism, method of treating diseases related to calcium metabolism and / or phosphate - Google Patents

Pharmaceutical composition containing bisphosphonate for the treatment of diseases related to calcium and / or phosphate metabolism, their use in the preparation of medicament for the treatment of diseases related to calcium and / or phosphate metabolism, method of treating diseases related to calcium metabolism and / or phosphate

Info

Publication number
BR0106601A
BR0106601A BR0106601-3A BR0106601A BR0106601A BR 0106601 A BR0106601 A BR 0106601A BR 0106601 A BR0106601 A BR 0106601A BR 0106601 A BR0106601 A BR 0106601A
Authority
BR
Brazil
Prior art keywords
calcium
phosphate
metabolism
diseases related
treatment
Prior art date
Application number
BR0106601-3A
Other languages
Portuguese (pt)
Inventor
Alcebiades De Mendonca Athayde
Original Assignee
Libbs Farmaceutica Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Libbs Farmaceutica Ltda filed Critical Libbs Farmaceutica Ltda
Priority to BR0106601-3A priority Critical patent/BR0106601A/en
Publication of BR0106601A publication Critical patent/BR0106601A/en

Links

Abstract

"COMPOSIçãO FARMACêUTICA CONTENDO BISFOSFONATO PARA O TRATAMENTO DE DOENçAS RELACIONADAS AO METABOLISMO DE CáLCIO E/OU FOSFATO, SEU USO NA PREPARAçãO DE MEDICAMENTO PARA O TRATAMENTO DE DOENçAS RELACIONADAS AO METABOLISMO DE CáLCIO E/OU FOSFATO, MéTODO DE TRATAMENTO DE DOENçAS RELACIONADAS AO METABOLISMO DE CáLCIO E/OU FOSFATO". A presente invenção refere-se a uma composição farmacêutica contendo bisfosfonato e agente quelante, para o tratamento de doenças relacionadas ao metabolismo de cálcio e/ou fosfato, por exemplo osteoporose, Doença de Paget, ossificação heterotrópica e hipercalcemia relacionada a câncer. A invenção refere-se ainda ao uso dessa composição na preparação de um medicamento útil no tratamento das doenças mencionadas, assim como ao método de tratamento de tais doenças."PHARMACEUTICAL COMPOSITION CONTAINING BISPHOSPHONATE FOR THE TREATMENT OF CALCIUM AND / OR PHOSPHATE-RELATED DISEASES, ITS USE IN THE PREPARATION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF CALCIUM METABASE AND / OR MOSPHETHESE-RELATED METABOLISM DISEASES CALCIUM AND / OR PHOSPHATE ". The present invention relates to a pharmaceutical composition containing bisphosphonate and chelating agent for the treatment of diseases related to calcium and / or phosphate metabolism, for example osteoporosis, Paget's disease, heterotropic ossification and cancer-related hypercalcemia. The invention further relates to the use of such a composition in the preparation of a medicament useful in treating the aforementioned diseases as well as to the method of treating such diseases.

BR0106601-3A 2001-12-21 2001-12-21 Pharmaceutical composition containing bisphosphonate for the treatment of diseases related to calcium and / or phosphate metabolism, their use in the preparation of medicament for the treatment of diseases related to calcium and / or phosphate metabolism, method of treating diseases related to calcium metabolism and / or phosphate BR0106601A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR0106601-3A BR0106601A (en) 2001-12-21 2001-12-21 Pharmaceutical composition containing bisphosphonate for the treatment of diseases related to calcium and / or phosphate metabolism, their use in the preparation of medicament for the treatment of diseases related to calcium and / or phosphate metabolism, method of treating diseases related to calcium metabolism and / or phosphate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR0106601-3A BR0106601A (en) 2001-12-21 2001-12-21 Pharmaceutical composition containing bisphosphonate for the treatment of diseases related to calcium and / or phosphate metabolism, their use in the preparation of medicament for the treatment of diseases related to calcium and / or phosphate metabolism, method of treating diseases related to calcium metabolism and / or phosphate

Publications (1)

Publication Number Publication Date
BR0106601A true BR0106601A (en) 2003-09-09

Family

ID=27768111

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0106601-3A BR0106601A (en) 2001-12-21 2001-12-21 Pharmaceutical composition containing bisphosphonate for the treatment of diseases related to calcium and / or phosphate metabolism, their use in the preparation of medicament for the treatment of diseases related to calcium and / or phosphate metabolism, method of treating diseases related to calcium metabolism and / or phosphate

Country Status (1)

Country Link
BR (1) BR0106601A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645460B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
EP2269584A1 (en) 2004-05-24 2011-01-05 Warner Chilcott Company, LLC Enteric solid oral dosage form of a bisphosphonate containing a chelating agent
US20130177645A1 (en) * 2004-05-24 2013-07-11 Warner Chilcott Company, Llc Low dosage forms of risedronate or its salts

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645460B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
EP2269584A1 (en) 2004-05-24 2011-01-05 Warner Chilcott Company, LLC Enteric solid oral dosage form of a bisphosphonate containing a chelating agent
EP2283825A1 (en) 2004-05-24 2011-02-16 Warner Chilcott Company, LLC Enteric solid oral dosage form of a bisphosphonate containing a chelating agent
US8246989B2 (en) 2004-05-24 2012-08-21 Warner Chilcott Company, Llc Dosage forms of bisphosphonates
US20130177645A1 (en) * 2004-05-24 2013-07-11 Warner Chilcott Company, Llc Low dosage forms of risedronate or its salts

Similar Documents

Publication Publication Date Title
BG100911A (en) Biophosphonic acids-sontaining wet-granulated form
BR0107755A (en) Parenteral composition, process for preparing and using this composition, process for the treatment and prevention of diseases that involve bone resorption and a device for sustained local and systemic release
ES2190244T3 (en) USE OF THE PARTIROID HORMONE CONSTITUTED BY A SEQUENCE OF AMINO ACIDS 1-34 OF THE HUMAN PARTIROID HORMONE TO REDUCE THE RISK OF VERTEBRAL AND NON-VERTEBRAL BONE FRACTURES.
ATE298790T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING PHOSPHATASE OR A CORRESPONDING DERIVATIVE
BR9714082A (en) Compound, use thereof, pharmaceutical composition, and, processes for treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound.
BR0214289A (en) Beverage composition comprising a defined boron compound, method of preparing it, kit comprising it and use thereof in the manufacture of a medicament
BR0010808A (en) Pharmaceutical compositions and uses
WO2005025504A3 (en) Modulators of calcitonin and amylin activity
BR0010257A (en) Compound, process for the preparation of a compound, pharmaceutical formulation, use of a compound, method for treatment or prophylaxis of conditions associated with the inhibition of carboxypeptidase u, kits of parts, and method of treating a patient suffering from or susceptible to a condition where inhibition of carboxypeptidase and a different antithrombotic mechanism are needed or desired
BR0017329A (en) Pharmaceutical formulation of a medicament, use of melatonin in the manufacture of a medicament, and method for preventing or treating symptoms of tardive dyskinesia in a patient using such medicament.
BR0106601A (en) Pharmaceutical composition containing bisphosphonate for the treatment of diseases related to calcium and / or phosphate metabolism, their use in the preparation of medicament for the treatment of diseases related to calcium and / or phosphate metabolism, method of treating diseases related to calcium metabolism and / or phosphate
PT1392325E (en) METHOD OF ADMINISTRATION OF BIFPHOSPHONATES BY INHALATION IN TREATMENT OR PREVENTION OF OSHA REOPSORCA AND OSTEOPOROSIS
BR9808233A (en) Pharmaceutical preparation
BR0212249A (en) Compound, pharmaceutical composition, method of treatment or prophylaxis of diseases, and use of a compound
BRPI0116865B8 (en) composition comprising bisphosphonates for the prevention and/or treatment of metabolic bone diseases, process for preparing such composition and use thereof
DE68919673D1 (en) METHOD FOR TREATING AND PREVENTING LOSS OF BONE MASS.
BRPI0409387B8 (en) thorium-227 soft tissue bleaching complex and a complexing agent, use thereof, pharmaceutical composition, method for forming a complex, and kit for use in a method for treating soft tissue disease in a mammalian subject
PT1089761E (en) MEDICINAL PRODUCT CONTAINING BISPHOSPHONIC ACIDS AND ITS DERIVATIVES FOR PROPHYLAXIS AND FOR THE TREATMENT OF SELF-IMMUNOLOGICAL DISEASES AS WELL AS ALLERGIES
Wigington et al. Pamidronate and 1, 24 (S)-dihydroxyvitamin D2 synergistically inhibit the growth of myeloma, breast and prostate cancer cells
BR0307021A (en) Use of alkylphosphocholines in the preventive treatment of protozoan diseases
BRPI0418122A (en) controlled release pharmaceutical formulation
WO2005074944A1 (en) Use of sodium neridronate to promote new bone formation
BR0112447A (en) Cyclic substituted aminomethyl compounds and medicinal products containing these compounds

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 7A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2014 DE 11/08/2009.